论文部分内容阅读
目的:观察益肺汤联合吉非替尼治疗肺癌脑转移头痛患者的临床效果。方法:将98例肺癌转移头痛患者随机分为研究组(n=50)与对照组(n=48),研究组患者采用益肺汤联合吉非替尼结合常规放疗治疗,对照组患者采用紫杉醇联合常规放疗治疗,观察比较两组患者的临床疗效。结果:经过治疗,研究组患者治疗总有效率为54.00%,明显高于对照组的33.33%,差异具有统计学意义(P<0.05);研究组患者呕吐、恶心、腹泻、白细胞下降、皮疹、转氨酶升高等不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05);研究组患者总生存期为(14.67±2.74)个月,明显高于对照组(7.69±2.08)个月,差异具有统计学意义(P<0.05)。结论:益肺汤联合吉非替尼治疗肺癌转移头痛效果显著,可显著减少患者肿瘤病灶,延长其生存期,降低不良反应发生率,有效提高生存质量,值得临床推广应用。
Objective: To observe the clinical effects of Yifei Decoction combined with gefitinib on patients with headache of brain metastasis of lung cancer. Methods: Ninety-eight patients with lung cancer with headache were randomly divided into study group (n = 50) and control group (n = 48). The study group was treated with Yifei Decoction combined with gefitinib with conventional radiotherapy. Patients in the control group were treated with paclitaxel Combined with conventional radiotherapy, the clinical efficacy was observed and compared between the two groups. Results: After treatment, the total effective rate of study group was 54.00%, significantly higher than that of the control group (33.33%), the difference was statistically significant (P <0.05); the study group patients vomiting, nausea, diarrhea, leukopenia, rash, (P <0.05). The overall survival rate of the study group was (14.67 ± 2.74) months, which was significantly higher than that of the control group (7.69 ± 2.08), and the incidence of adverse reactions such as elevated aminotransferase was significantly lower than that of the control group Month, the difference was statistically significant (P <0.05). Conclusion: Yifei Decoction combined with gefitinib has a significant effect on the treatment of lung cancer headache. It can significantly reduce the tumor focus, prolong the survival time, reduce the incidence of adverse reactions and effectively improve the quality of life. It is worthy of clinical application.